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Cardiovascular diseases remain the leading cause of
death. The majority of these diseases involve a pathogenic
process: atherosclerosis (1). Hyperlipidemia is the primary
atherogenic risk factor (1, 2). In the plasma, lipids are
encapsulated particles with apoproteins (1). High-density
lipoproteins (HDL) transport lipids from peripheral tissues
to the liver and, thus, are antiatherogenic (1). Low-density
lipoproteins (LDL) are the major type of lipoproteins
accumulated in the subendothelial matrix and, hence, are
atherogenic. LDL is derived from very low-density lipoproteins (VLDL), which are assembled in and secreted by
the liver (2). VLDL assembly starts when apolipoprotein
B-100 (apo-B100) is translated and translocated into endoplasmic reticulum (ER). Maturation of VLDL particles
undergoes multiple lipidation processes that traverse from
the ER and post-ER/Golgi compartments (2). Lipids incorporated into VLDL particles undergo continuous
hydrolysis/reesterification.
Carboxylesterase-1 (CES1) in humans and its functionally related mouse counterpart (Ces1d) in lipid catabolism
are implicated in the hydrolysis/reesterification cycle (3, 4).
Indeed, higher CES1 activity facilitates VLDL maturation
(5), and transgenic expression of CES1 leads to increased
secretion of apoB proteins (3). Conversely, hydrolysis of
cholesterol esters by CES1 is linked to cholesterol elimination (6). In the classic pathway of bile acid synthesis, cholesterol is oxidized by cytochrome 7A1 (CYP7A1) (7), eventually
converted into bile acids, and secreted by the bile acid
export pump (BSEP). The secretion of bile acids represents the net elimination of excessive cholesterol (8).

Abstract Z-Guggulsterone is a major ingredient in the
Indian traditional hypolipidemic remedy guggul. A study
in mice has established that its hypolipidemic effect involves the farnesoid X receptor (FXR), presumably by acting as an antagonist of this receptor. It is generally assumed
that the antagonism leads to induction of cytochrome P450
7A1 (CYP7A1), the rate-limiting enzyme converting free
cholesterol to bile acids. In this study, we tested whether
Z-guggulsterone indeed induces human CYP7A1. In addition, the expression of cholesteryl ester hydrolase CES1
and bile salt export pump (BSEP) was monitored. Contrary
to the general assumption, Z-guggulsterone did not induce
CYP7A1. Instead, this phytosterol significantly induced
CES1 and BSEP through transactivation. Z-Guggulsterone
underwent metabolism by CYP3A4, and the metabolites
greatly increased the induction potency on BSEP but not on
CES1. BSEP induction favors cholesterol elimination,
whereas CES1 involves both elimination and retention
(probably when excessively induced). Interestingly, clinical
trials reported the hypolipidemic response rates from 18%
to 80% and showed that higher dosages actually increased
VLDL cholesterol. Our findings predict that better hypolipidemic outcomes likely occur in individuals who have
a relatively higher capacity of metabolizing Z-guggulsterone
with moderate CES1 induction, a scenario possibly achieved
by lowering the dosing regimens.—Yang, D., J. Yang, D. Shi,
D. Xiao, Y-T. Chen, C. Black, R. Deng, and B. Yan. Hypolipidemic agent Z-guggulsterone: metabolism interplays with
induction of carboxylesterase and bile salt export pump.
J. Lipid Res. 2012. 53: 529–539.

EXPERIMENTAL PROCEDURES
RT-qPCR
Human primary hepatocytes were obtained from the Liver
Tissues Procurement and Distribution System (University of
Minnesota) or CellzDirect (Pittsboro, NC). The use of the human
samples was approved by the Institutional Review Board. Hepatocytes and hepatoma cells (Huh7) were cultured and treated with
Z-guggulsterone, chenodeoxycholic acid (CDCA), or both as described previously (12). The mRNA levels were determined with
TaqMan assays (16). The assay identification numbers were CES1,
Hs00275607_m1; CYP7A1, Hs00167982_m1; BSEP, Hs00184824_
m1; GAPDH, 4352934E; and RNA polymerase II, Hs00172187_m1.
The CES1 probe recognized both CES1A1 and CES1A2, and both
enzymes are identical, although encoded by distinct genes (17).

Reporter assays
The BSEP guggulsterone element reporter and the FXR expression construct were described elsewhere (12). The CES1A1 reporters containing the promoter and its upstream sequence at varying
lengths were prepared by inserting the corresponding genomic
fragment into the pGL3 basic luciferase vector at the Mlu I and
Xho I sites. All genomic fragments were generated by PCR with
high-fidelity Platinum Taq DNA polymerase. The primer sequences
are listed in Table 1. Initially, human genomic DNA from the placenta was used as the template for the amplification of the genomic
fragment from -7714 to -21 (from the initial translation codon)
with primers CES1A1-21XhoIa and 7714MluIs. This fragment was
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inserted into the pGL3 basic luciferase vector to prepare reporter
CES1A1-7714Luc. This construct was then used as the template to
prepare reporters: CES1A1-6981Luc, CES1A1-3582Luc, CES1A13432Luc, and CES1A1-2932Luc with the same antisense primer
(CES1A1-21XhoIa) but different sense primer (Table 1). The reporters CES1A1-9622Luc and CES1A1-9332Luc contained additional upstream sequences. To prepare these constructs, human
genomic DNA was used as the template with primers CES1A14777a and CES1A1-9622Mlus or CES1A1-9333MluIs. The respective fragments were digested with Mlu I and Spe I (an internal site
in the fragments). The digested fragments were then ligated to the
reporter CES1A1-7714Luc pretreated with the same endonucleases. The CES1A1 guggulsterone element reporter was prepared
by inserting the oligonucleotides (5′-CACAATCTGCAGAGTCATCATGAAG-3′) into the pGL3 promoter vector at the Nhe I and
Xho I sites. All constructs were confirmed by sequencing. The reporter assays were performed as described previously (12).

Metabolism of Z-guggulsterone
Metabolism was conducted with recombinant CYPs (1 pmol)
and pooled human liver microsomes (20 g) in a total volume of
100 l (18, 19). Preliminary studies were performed to determine conditions supporting the linear rate. Z-Guggulsterone was
dissolved in acetonitrile, and the final concentration of the solvent was 0.1%. After 10 min preincubation at 37°C, reactions
were initiated by adding the NADPH-regenerating system (NRS)
and then were incubated for 40 min. The reactions were terminated by two volumes of ice-cold acetonitrile containing the
internal standard spironolactone (10 g/ml), followed by centrifugation. For the inhibition assay, the prereaction mixtures
contained a CYP inhibitor at previously reported concentrations
(20). The metabolism was monitored for the disappearance of
Z-guggulsterone by LC-MS/MS (API 3200) (19). Detection of the
analytes was performed in positive ion mode using the mass
transitions of m/z 313.2→97.0 for Z-guggulsterone and m/z
416.6→341.2 for IS. Injection analysis was performed at a flow
rate of 200 l/min to obtain optimum source parameters. The
assay was linear from 1.04 to 416.27 ng/ml for Z-guggulsterone.

Purification of metabolites
Reactions were set up in a total volume of 1 ml with CYP3A4.
The supernatants were separated on a Chromolith SpeedROD
column RP-18e (Merck, Germany) by a gradient mobile phase
made of 0.1% aqueous formic acid (A) and acetonitrile (B). The
mobile phase started with 10% acetonitrile for 2 min, 15% for
5 min, 70% for 3 min, 30% for 4 min, and 10% for 1 min with the
flow rate of 2 ml/min. The metabolites were detected by a diode
array detector at 240 nm. The concentrated metabolites were
analyzed by HPLC, and the concentrations were estimated according to the curve generated with Z-guggulsterone at various
concentrations. The metabolites were analyzed for the massto-charge ratios by a Q-Star Elite time-of-flight mass spectrometer
(Applied Biosystems/MDS SCIEX). The LC conditions were the
same as described above but with a reduced flow rate (0.5 ml/
min). Analytic parameters were as follows: injection volume, 20 l;
column temperature, 30°C; DAD range, 210–400 nm with 240 as
the detection wavelength; ionization mode, ESI+; scan range,
220–500 amu; and scan rate, 1 scan/s.

Mouse hepatocyte culture and treatment
Primary mouse hepatocytes were isolated from 9-week-old
CD-1 mice (male) by a modified two-step collagenase digestion
method, essentially as described previously (21). Hepatocytes
were dispersed from the digested liver in Williams’ Medium E
(Sigma-Aldrich, St. Louis, MO) without collagenase and washed
by low-speed centrifugation (100–150 g, 5 min) three times. Hepatocytes were suspended in Williams’ Medium E containing
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Increased bile acid synthesis has long been explored for
the development of drugs with cholesterol-lowering activity.
The biliary secretion has a large capacity and is equally
effective in eliminating both endogenous and dietary cholesterols. For quite some time, guggul has gained interest
worldwide (9–11). Originally described in the Indian traditional medicine Ayurveda, guggul has been used for
thousands of years to treat conditions such as atherosclerosis (9, 12). The hypolipidemic activity has been confirmed in multiple animal models (9). Human clinical trials,
however, produced inconsistent results. Some clinical
trials reported that guggul lowered plasma cholesterol
by 20–30% and triglycerides by 10–20%, with the response
rate being as high as 80% (9, 13, 14). Other trials, however,
did not detect the same level of effectiveness (10, 11).
Nonetheless, Z-guggulsterone is recognized as the major
active ingredient. Its hypolipidemic activity in mice requires
the farnesoid X receptor (FXR) (15). This phytosterol is
an antagonist of FXR, and such antagonism is assumed to
accelerate bile acid synthesis by inducing CYP7A1. To
directly test this hypothesis, human primary hepatocytes
were treated with Z-guggulsterone, and the expression
of CYP7A1 was determined. In addition, the expression of
CES1 and BSEP was monitored. Contrary to the general
assumption, Z-guggulsterone was an inducer of CES1 and
BSEP but not of CYP7A1. In addition, Z-guggulsterone was
metabolized, and the metabolites differentially altered
CES1 and BSEP induction. Our findings predict that the
hypolipidemic activity of Z-guggulsterone depends on two
important interplays: CES1 induction versus CYP7A1
activity, and the metabolism of Z-guggulsterone versus
the relative inducibility between CES1 and BSEP.

TABLE 1.

Sequences of primers for reporter constructs

Primer

CES1A1-21XhoIa
CES1A1-7713MluIs
CES1A1-6980MluIs
CES1A1-3582MluIs
CES1A1-3432MluIs
CES1A1-2931MluIs
CES1A1-4777a
CES1A1-9622MluIs
CES1A1-9332MluIs

Sequence

Reporter

5′-tcggggcctgcgaggtctcttgcagttca-3′
5′-taaggtggatggattacctgaggtcaggagt-3′
5′-ttgcatgtcaaagtgtcagaatggagaaat-3′
5′-ttattgcttacagctgaagtg-3′
5′-tcaggcaaaacctaggagtgg-3′
5′-tccagcctgcacgtggctaga-3′
5′-catagctagccaccctcaatggcgcaaaca-3′
5′-tgacacgcgtaccaactcagtccagattcccccagggcag-3′
5′-tgacacgcgtaagagctcgctgtgctccatgaatggggtg-3′

All promoter reporters
CES1A1-7714Luc
CES1A1-6981Luc
CES1A1-3582Luc
CES1A1-3432Luc
CES1A1-2932Luc
1A19622 and 9332Luc
CES1A1-9622Luc
CES1A1-9332Luc

by increasing bile acid synthesis through inducing CYP7A1.
On the other hand, rats fed with guggul herb extract did
not show increased expression of CYP7A1 (26). Nevertheless, we made an effort to determine whether Z-guggulsterone induces human CYP7A1. Human primary hepatocytes
were treated with Z-guggulsterone, and the expression was
determined. CDCA, a known suppressor of CYP7A1 (27),
was included in this study as a negative control. Contrary
to the general assumption, Z-guggulsterone caused a 20%
decrease of CYP7A1 mRNA (Fig. 1B), although the decrease did not reach statistical significance. As expected,
CDCA significantly decreased CYP7A1 mRNA (Fig. 1B).
The decrease was partially reversed by Z-guggulsterone

Electrophoresis-coupled activity determination
Nondenaturing gel electrophoresis for staining esterase activity was conducted as described previously (22). Cell lysates (5 or
20 g) was solubilized with 0.2% Lubrol and subjected to electrophoresis with a 3% acrylamide stacking gel and a 7.5% acrylamide separating gel. After electrophoresis, the gels were washed for
1 h in 100 mM potassium phosphate buffer (pH 6.5), followed by
incubating in the same buffer containing 1-naphthylacetate
(5 mM) and 4-benzolamino-2,5-dimethoxybenzenediazonium
chloride hemi (zinc chloride) salt, usually termed Fast Blue RR
(0.4 mg/ml). The staining of esterases by this method is based on
the formation of a black, insoluble complex between 1-naphthol
hydrolyzed from 1-naphthylacetate and Fast Blue RR.

Other analyses
Electrophoretic mobility shift assay (EMSA) was performed as
described previously (21, 23). Western blotting was detailed elsewhere (19, 24). Preparation of CES1 antibody against a peptide
was described previously (25). The antibody (PC-064) against
BSEP (mouse and human) was purchased from Kamiya Biomedical Co. (Seattle, WA), the antibody against human CYP7A1
(ab79847) from Abcam, Inc. (Cambridge, MA), and the antibody
against mouse cyp7a1 from Cosmo Bio Co. (Western Carlsbad,
CA). Significant differences were determined by one-way ANOVA
followed by a Duncan’s multiple comparison test (P < 0.05).

RESULTS
Z-Guggulsterone induces CES1 and BSEP
but not CYP7A1
It is generally assumed that Z-guggulsterone exerts hypolipidemic activity based on a feed-back mechanism (7)

Fig. 1. Effect of Z-guggulsterone on the expression of CES1,
CYP7A1, and BSEP. (A) Chemical structure of Z-guggulsterone.
(B–D) Regulated expression in human primary hepatocytes. Hepatocytes (n = 4–8) were treated with Z-guggulsterone (10 M),
CDCA (10 M), or both for 24 h. DMSO (0.1%) was used as the
control. The mRNA levels of CES1, CYP7A1, BSEP, GAPDH, or
polymerase II by Taqman probes. Columns labeled with a different
letter were statistically significant (P < 0.05). To determine the
changes in the protein level, lysates (0.5 µg for CES1 and 20 µg for
CYP7A1 or BSEP) from pooled samples (n = 4) were resolved by
7.5% SDS-PAGE and transferred electrophoretically to nitrocellulose membranes. The blots were incubated with an antibody against
CYP7A1, CES1, or BSEP and then developed with chemiluminescent substrate and reprobed by GAPDH antibody. The signal was
captured by Carestream 2200 PRO Imager.
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35% percoll. The resulting cell pellet was then suspended in
Williams’ Medium E containing 10% fetal bovine serum, insulintransferrin-sodium selenite (ITS) supplement, and dexamethasone (100 nM). Cell viability was determined by trypan blue
exclusion. Hepatocytes were then plated onto collagen-coated
12-well culture plates. The cells were allowed to attach for 4 h at
37°C in a humidified chamber with 95%/5% air/CO2. Culture
plates were then gently swirled, and the medium containing unattached cells was aspirated. Fresh medium (free serum) was
added to each well, and the cultures were returned to the humidified chamber. Hepatocytes were cultured in the same medium
for 48 h, but the medium was changed at 24 h. Thereafter, hepatocytes were cultured in DMEM containing treatment chemicals at
appropriate concentrations for 48 h; the treatment medium was
replaced once at 24 h. Treated hepatocytes were collected in RIPA
buffer for Western blotting. Otherwise, hepatocytes were collected
in Tris-HCl (50 mM, pH 7.4), and lysates were prepared by sonication as described previously (21). All mice were allowed free access
to Purina Rodent Chow 5001 and water, and the use of animals was
approved by the Institutional Animal Care and Use Committee.

(Fig. 1B). The level of CYP7A1 protein showed a pattern of
changes similar to the level of CYP7A1 mRNA. In contrast
to the suppression of CYP7A1, Z-guggulsterone significantly induced both CES1 and BSEP mRNA with BSEP
(Fig. 1C, D). The fold of induction of BSEP was higher
than that of CES1 in the primary hepatocytes (P < 0.05).
Cotreatment with CDCA synergistically increased BSEP
induction but slightly decreased CES1 induction (Fig. 1C, D).
As seen with CYP7A1, the levels of CES1 and BSEP proteins exhibited patterns of changes similar to those of the
respective mRNA levels.
Activation of the CES1A1 promoter
We have shown that Z-guggulsterone induces BSEP
through transactivation (12). Next, we tested whether
transactivation is also involved in CES1 induction. Huh7
cells (a human hepatic line) were used for this study.

Initially, concentration-dependent induction was determined in this line. As shown in Fig. 2A, Z-guggulsterone
induced CES1 and BSEP mRNA in a concentrationdependent manner; however, the magnitude of induction varied markedly. Both genes were induced comparably
at lower concentrations, but CES1 mRNA was induced
to a significantly greater extent at 10 and 20 µM. All data
points on CES1 induction significantly differed from each
other (P < 0.05), except those between 0.5 and 1 µM. Likewise, all concentrations caused statistically significant induction of BSEP. However, the magnitudes of the inductions
between 0.5 and 1 µM did not differ significantly, and neither did those among 5, 10, and 20 µM. Next, we tested
whether actinomycin D, a transcriptional inhibitor, abolishes the induction of both CES1 and BSEP. Huh7 cells
were treated with Z-guggulsterone in the presence or absence of actinomycin D. As shown in Fig. 2B, cotreatment
Downloaded from www.jlr.org at Univ of Rhode Island, on November 19, 2018

Fig. 2. Stimulation of the CES1A1 promoter. (A) Concentration-dependent induction of CES1 and BSEP
Huh7 cells were treated with Z-guggulsterone (Gugg) at various concentrations (0–20 µM) for 24 h, and
then the levels of CES1 and BSEP mRNA were determined as described above. An asterisk indicates statistical
significance of a treatment over solvent control, and an alpha indicates statistical significance between two
columns linked by a line (P < 0.05). (B) Effect of actinomycin D (Act D) on induction. Huh7 cells were
treated with Z-guggulsterone (5 M) for 24 h in the absence or presence of actinomycin D (1 M), and the
levels of CES1 and BSEP mRNA were determined. An asterisk indicates statistical significance of a treatment
over solvent control (P < 0.05). (C) Activation of CES1A1 reporters. Huh7 cells were seeded in 48-well plates.
After an overnight incubation, the cells were transfected with a reporter (50 ng) along with 5 ng of the nullRenilla luciferase plasmid. The transfected cells were treated with Z-guggulsterone (10 M) or the same
volume of DMSO for 24 h. Luciferase activities were determined with a dual-luciferase reporter assay. Data
in this figure are from three separate experiments.
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contained three copies. Nevertheless, EMSA with nuclear
extract from Z-guggulsterone treated Huh7 cells detected
a shifted band with the CES1A1 element. This binding was
competed effectively by the corresponding nonlabeled
element (Fig. 3B). In contrast, the mutant element (5′-CACAATGTACTGAGGAATCATGAAG-3) had no competitive effect (Fig. 3B).
Metabolism by CYP3A4
As described in Figs. 1 and 2, BSEP mRNA was induced
higher in primary hepatocytes, whereas CES1 mRNA was
induced comparably or higher in Huh7 cells, depending
on the concentrations. One explanation is that primary
hepatocytes express higher basal levels of CES1 and, thus,
the inducibility is lower. Another explanation is that primary hepatocytes, but not Huh7 (28), effectively metabolize
Z-guggulsterone. To test whether Z-guggulsterone actually
undergoes metabolism, incubations were performed with
pooled human liver microsomes in the presence or absence
of the NADPH-regenerating system. This system is required
for reactions catalyzed by CYPs and flavin monooxygenases
(28). As shown in Fig. 4A, the reaction incubated without
NRS, like zero-minute incubation, yielded a peak with a retention time of 7.92 min (i.e., Z-guggulsterone). This peak,

Fig. 3. Characterization of CES1A1 guggulsterone element. (A) Stimulation of the CES1A1 and BSEP element reporters. Reporter assays were performed as described above but with element reporters. An asterisk
indicates statistical significance of a treatment over solvent control, and an alpha indicates statistical significance between two columns linked by a line (P < 0.05). (B) EMSA analysis. Nuclear extracts (5 g) from
Huh7 cells treated with Z-guggulsterone (10 M) were incubated with a biotinylated probe (0.01 pmol) for
20 min. In the competition assay, nuclear extracts were preincubated with the unlabeled probe or mutant at
50× (+) or 100× (++) excess for 20 min, and then incubated with the biotinylated probe. The protein-DNA
complexes were electrophoretically resolved and detected with streptavidin-conjugated horseradish peroxidase and chemiluminescent substrate.

Interplay between CES1 and BSEP induction by Z-guggulsterone
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with actinomycin D completely abolished the induction of
both CES1 and BSEP, suggesting that Z-guggulsterone
induces CES1, like BSEP (12), through transactivation.
We next tested whether Z-guggulsterone stimulates the
promoter of CES1A1, the predominant form of the
CES1 genes (17). As shown in Fig. 2C, all reporters were
activated by Z-guggulsterone, except reporters CES1A13432luc and CES1A1-2932Luc. The maximum activation
was 6-fold and occurred with the reporter CES1A1-3582Luc (Fig. 2C). CES1A1-3432luc, the immediate reporter
shorter than CES1A1-3582Luc, no longer responded to
Z-guggulsterone, suggesting that this 150-bp genomic
fragment (-3582 to -3432) supports the transactivation.
To precisely specify the sequence for the transactivation, element reporters (20–25 bases each) were prepared
to span the entire region with overlapping sequence.
Among the element reporters, only one reporter, designated CES1A1Gugg-Luc, responded to Z-guggulsterone
(Fig. 3A). This and the BSEPGugg-Luc reporter were
tested for the activation as a function of Z-guggulsterone.
As shown in Fig. 3A, the CES1A1 element reporter was
activated much higher, except at the 20 µM data point
(Fig. 3A). Note that the CES1 reporter contained only a
single copy of the element, whereas the BSEP reporter

(Fura) and ketoconazole (Keto), all inhibitors caused a
10–20% decrease in the metabolism (Fig. 4B). Ketoconazole
caused complete inhibition, whereas the CYP1A2 inhibitor
furafylline caused no inhibition. Isoform-specific substrates
were used to confirm the activity of each inhibitor.
The inhibition study demonstrated that multiple CYPs
metabolized Z-guggulsterone, with the CYP3A4 being the
most active. To directly test this possibility, recombinant
CYPs were tested for metabolism. Consistent with the inhibition study, CYP3A4 had the highest activity (Fig. 4C).
Moderate metabolism was detected with CYP1A2, 2A6,
and 2B6; slight metabolism was detected with CYP2C19
and 2D6; and no metabolism was detected with CYP2C8,
2C9, and 2E1 (Fig. 4C). Interestingly, CYP1A2 was the second most active toward Z-guggulsterone, although the corresponding inhibitor showed no activity (Fig. 4B). Specific
substrates for each CYP were included to verify the catalytic
activity of each recombinant CYP.

however, disappeared by ⵑ90% when the incubation was
performed in the presence of NRS (Fig. 4A). At the same
time, several metabolite peaks appeared with a retention
time of 4.69 min (M1), 5.60 (M2), 5.92 (M3), and 6.56
(M4), respectively. M3 was the most abundant (Fig. 4A).
The majority of oxidations are catalyzed by the CYP system
(28). We next tested whether one or more CYPs metabolize
Z-guggulsterone. Incubations were conducted with pooled
microsomes but in the presence of a CYP inhibitor. A total of
nine inhibitors were used, including furafylline (CYP1A2),
pilocarpine (CYP2A6), thio-tepa (CYP2B6), quercetin
(CYP2C8), sulfaphenazole (CYP2C9), ticlopidine (CYP2C19),
quinidine (CYP2D6), chlormethiazole (CYP2E1), and ketoconazole (CYP3A4/5). With the exceptions of furafylline
534
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Induction potency of major metabolites
To determine whether the metabolites and Z-guggulsterone differ in the induction potency, RT-qPCR and reporter assays were performed. The concentrations of the
metabolites were estimated based on the area under the
curve. This study included all major metabolites except
M2, which was not sufficient to generate the standardized concentration (2 µM). Compared with Z-guggulsterone, all metabolites caused significant increases in the
level of BSEP mRNA (Fig. 6A), with M3 causing the highest increase (> 3-fold). In contrast, the magnitude of
changes in CES1 mRNA was much less. Compared with
Z-guggulsterone, M1 caused a 47% increase, M3 caused a
12% decrease, and M4 caused a 22% increase in CES1
induction (Fig. 6A). All metabolites tested showed significantly higher induction of BSEP than CES1 mRNA
(Fig. 6A).

Downloaded from www.jlr.org at Univ of Rhode Island, on November 19, 2018

Fig. 4. Metabolism of Z-guggulsterone. (A) Chromatograms generated by pooled human liver microsomes. The incubations were
performed at 37°C in a total volume of 100 l containing pooled
human liver microsomes (20 g) and Z-guggulsterone (10 M) in
the presence of NRS. The incubations lasted for 90 min. The
elution trace was generated at 240 nm by injecting 20 l supernatants. (B) Inhibited metabolism of Z-guggulsterone. Z-guggulsterone (10 M) was metabolized by microsomes (20 g) in the
presence or absence of a CYP inhibitor: 50 M furafylline, 100 M
pilocarpine, 75 M thio tepa A, 10 M quercetin, 20 M sulfaphenazole, 1 M ticlopidine, 10 M quinidine, 100 M chlormethiazole, or 1 M ketoconazole. The reactions lasted for 40 min.
The disappearance of Z-guggulsterone was monitored. The percentage of inhibition was calculated. (C) Metabolism by recombinant CYPs. The incubations were performed with a recombinant
CYP (1 pmol) and Z-guggulsterone (10 l) for 40 min. All experiments were conducted twice with each in triplicate.

Purification of major metabolites
To determine whether the metabolism alters the induction potency, we purified several major metabolites.
Initially, we performed a time-course study to determine
the kinetics of the metabolism by recombinant CYP3A4. As
shown in Fig. 5A, the parent compound was disappeared
by ⵑ70% within 30 min of incubation. Prolonged incubation further increased the metabolism. The metabolite
profile generated by CYP3A4 was very similar to that generated by liver microsomes (Figs. 4A and 5A), confirming
that this CYP is the primary enzyme for the metabolism.
Interestingly, the 30 min incubation produced similar
amounts of M1 and M4; however, prolonged incubation
produced more M1 than M4 (Fig. 5A). To this end, we
purified M1, M2, M3, and M4 to homogeneity. As shown
in Fig. 5B–E, all purified metabolites produced a single
peak with a predicated retention time. Mass spectrometry
revealed that M1 was at m/z 345 and the other three metabolites at 329. Z-Guggulsterone had a mass-to-charge ratio of 313. Therefore, M1 represented an addition of two
hydroxyl groups, whereas the others resulted from an
addition of a single hydroxyl group.

We next tested the activation of CES1 and BSEP element
reporters by various metabolites. The results are summarized in Fig. 6B. The changes in element reporter activation, compared with those in the induction of CES1 and
BSEP mRNA, had several important differences. First, all
metabolites showed increases in the activation of the element reporters, which was not true in mRNA induction
(Fig. 6A, B). For example, metabolite M3 actually caused a
slight decrease in the induction of CES1 mRNA. Second,
between CES1A1 and BSEP, metabolites generally caused
less difference in the activation of the element reporters
than in induction of the mRNA (Fig. 6A, B). For example,
metabolite M1 caused much higher increases in the induction of BSEP mRNA than CES1 mRNA, whereas this metabolite caused similar increases in the activation of both
element reporters (Fig. 6A, B). And third, the overall
changes in the CES1 element reporter activation were
greater than those in the induction of CES1 mRNA. For
example, compared with Z-guggulsterone, the maximal
change in the induction by M1 was 47% increase (Fig. 6A),

whereas the maximal change in the activation by M1 was
ⵑ2-fold (Fig. 6B). To further determine whether CYP3A4based metabolism of Z-guggulsterone differentially alters
BSEP and CES1 induction, Huh7 cells were transfected
with CYP3A4 or the vector, treated with Z-guggulsterone
(5 µM), and then analyzed for the induction of CES1
and BSEP mRNA. As shown in Fig. 6C, cotransfection of
CYP3A4, compared with the vector, significantly increased
BSEP but not CES1 induction.
Effect of Z-guggulsterone on the expression of mouse
bsep, cyp7a1, and carboxylesterases (ces)
To determine whether Z-guggulsterone modulates the
expression of the corresponding mouse genes, mouse
primary hepatocytes were treated with Z-guggulsterone,
CDCA, or both. As shown in Fig. 7A, Z-guggulsterone significantly induced bsep but not cyp7a1, and inductions
were not affected by CDCA cotreatment. These responses
were consistent with the responses on the expression of
BSEP and CYP7A1 in rats fed with guggul extract (26).
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Fig. 5. Analyses of metabolites by HPLC and LC-MS. (A) Time-course metabolism by CYP3A4. The incubations were performed at 37°C
with 1 pmol CYP3A4 and 10 M Z-guggulsterone for 0–120 min. The HPLC elution trace was generated at 240 nm. (B–E) HPLC chromatogram and full scan of metabolites M1, M2, M3, and M4, respectively.

As expected, CDCA, a weak activator of mouse fxr (26),
caused little changes in the expression of bsep or cyp7a1
(Fig. 7A). Next we tested whether these treatments alter
the expression of mouse carboxylesterases. In terms of the
number of carboxylesterase genes, mice have almost three
times as many as humans (29). The relative level of carboxylesterases can be indirectly determined by nondenaturing electrophoresis, followed by staining for hydrolytic
activity with 1-naphythalacetate (22). This standard substrate can be hydrolyzed by many carboxylesterases. As
shown in Fig. 7B (left), both CDCA and Z-guggulsterone
markedly induced several major mouse carboxylesterases,
such as ces2e and ces2c, but not many others, such as
ces1d (the mouse counterpart of human CES1). The identity of some of the electrophoretically distinct mouse carboxylesterases remains to be established. As expected,
Z-guggulsterone significantly increased hydrolysis by CES1
but much less so by CES2 (Fig. 7B, right). Cotreatment
with CDCA slightly decreased the increased hydrolysis of
CES1 by Z-guggulsterone.

DISCUSSION
This study has shown that Z-guggulsterone significantly
induced CES1 and BSEP. The induction of CES1 by
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Z-guggulsterone, like the induction of BSEP, was achieved
by transactivation (Fig. 2). The transactivation depended
on a particular genomic sequence designated as the
CES1A1 guggulsterone element (Fig. 3A). Coincidently, both
CES1A1 and BSEP guggulsterone response elements contain an antioxidant response element (ARE) and an AP-1
site (Fig. 8A). However, the CES1A1 ARE is orientated in
an opposite direction to that of BSEP (Fig. 8A). Also, the
CES1A1 AP-1 site (AGAGTCA) slightly differs from that of
BSEP (TGAATCA) (Fig. 8A). More importantly, these two
elements differentially responded to Z-guggulsterone and
its metabolites, particularly metabolite M3 (Fig. 6B). Compared with Z-guggulsterone, M3 increased the activation
of the BSEP reporter from 2.6- to 7.3-fold, whereas the increase was much less in the activation of the CES1A1 reporter from 3.2- to 4.3-fold (Fig. 6B). On the other hand,
similar responses were detected between the reporter activation and mRNA induction of BSEP (Fig. 6A, B), whereas
the reporter activation of CES1 was much higher than the
corresponding mRNA induction (Fig. 6A, B). One explanation is that the BSEP element provides the primary
mechanism for BSEP induction by Z-guggulsterone,
whereas the CES1A1 element represents one of the mechanisms for CES1 induction.
Clearly, the metabolism of Z-guggulsterone is determined largely by CYP3A4. The metabolite profile generated
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Fig. 6. Functional characterization of the metabolites. (A) Differential induction of CES1 and BSEP Huh7
cells were treated with Z-guggulsterone (2 M) or a metabolite (2 M) for 24 h. The mRNA levels of CES1
and BSEP were determined. An asterisk indicates statistical significance of a metabolite over Z-guggulsterone, and an alpha indicates statistical significance between two columns linked by a line (P < 0.05). (B) Differential activation of CES1 and BSEP element reporters. Huh7 cells were seeded in 48-well plates. After
overnight incubation, the cells were transfected with a reporter (50 ng) and 5 ng of the null-Renilla luciferase plasmid. The transfected cells were treated with Z-guggulsterone (2 M), a metabolite (2 M), or
the same volume of DMSO for 24 h. The reporter luciferase activities (firefly) were normalized according to
the null-Renilla luciferase activities. An asterisk indicates statistical significance of a metabolite over Z-guggulsterone, and an alpha indicates statistical significance between two columns linked by a line (P < 0.05).
(C) Effect of CYP3A4 on the induction of CES1 and BSEP. Huh7 cells were seeded in 24-well plates at a den5
sity of 1.5 × 10 and cultured overnight. The cells were transfected with a CYP3A4 expression construct or the
corresponding vector (0.5 µg). The transfected cells were cultured for 24 h and then treated with Z-guggulsterone at 5 M for 24 h. Total RNA was isolated and analyzed for the levels of CES1 and BSEP mRNA. The
data were collected from three separate experiments. *P < 0.05.

by human microsomes was similar to that by CYP3A4
(Figs. 4A and 5A). On the other hand, there were several
interesting observations, particularly regarding the metabolism by CYP1A2 (Fig. 4B, C). Furafylline, an inhibitor of
CYP1A2, showed little inhibition of Z-guggulsterone metabolism by liver microsomes (Fig. 4B), yet recombinant
CYP1A2 significantly metabolized this phytosterol (Fig. 4C).
One explanation is that Z-guggulsterone is a substrate of
both CYP3A4 and CYP1A2, but CYP3A4 has higher affinity
and more efficiently metabolizes the phytosterol. In addition, CYP3A4 is two to three times more abundant than
CYP1A2 in the liver (28). Therefore, CYP1A2 normally

contributes less, if any, to the hepatic metabolism of Zguggulsterone. Another interesting observation was that
CYP3A4 produced various metabolites (Fig. 5A). Most of
them resulted from addition of a single hydroxyl group
(Fig. 5C–E). In contrast, the formation of M1 resulted
from addition of two hydroxyl groups (Fig. 5B). Prolonged
incubation increased the production of M1 but proportionally decreased M4 (Fig. 5A), suggesting that M4 is a
substrate of CYP3A4 to produce M1 (Fig. 5A).
Although the purified metabolites generally increased
the induction of both CES1 and BSEP, the magnitude was
much greater on BSEP (Fig. 6). Secretion of bile acids
represents net elimination of cholesterol (8); therefore,
induction of BSEP favors lowering cholesterol. In contrast,
induction of CES1 may favor the elimination or recycling
of cholesterol, probably depending on the level of CYP7A1
(Fig. 8B). Given that the action of CES1 leads to increased
free cholesterol, high levels of CYP7A1 in individuals
would facilitate the conversion of cholesterol into bile acids, whereas low levels of CYP7A1 in others would favor the
pathway of VLDL assembling (double-lined arrow in
Fig. 8B). Therefore, individuals with a high level of BSEP
induction relative to CES1 induction (probably with high
capacity of metabolizing guggulsterones) would benefit
more in lowering cholesterol. Accordingly, the purified
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Fig. 7. Effect of Z-guggulsterone, CDCA, and both on the expression of mouse bsep, mouse cyp7a1, and esterase activity staining.
(A) Expression of mouse bsep and cyp7a1. Mouse primary hepatocytes (n = 3) were treated with Z-guggulsterone (10 M), CDCA
(10 M), or both for 24 h. DMSO (0.1%) was used as the control.
Lysates (25 µg) were resolved by 7.5% SDS-PAGE and transferred
electrophoretically to nitrocellulose membranes. The blots were
incubated with an antibody against bsep or cyp7a1, developed with
chemiluminescent substrate, and reprobed by GAPDH antibody.
The signal was captured by Carestream 2200 PRO Imager. (B) Nondenaturing electrophoresis stained for hydrolytic activity. Mouse
primary hepatocytes and human HepG2 cells were treated as described above. Lysates from mouse hepatocytes (5 µg) or HepG2
cells (20 µg) were subjected to native gel electrophoresis and
stained for esterase activity with 1-naphythalacetate as described in
Experimental Procedures. The staining intensity was captured by
Carestream 2200 PRO Imager. Note the glycosylation variants of
CES.

Fig. 8. Response elements and interplays among CES1, BSEP,
and CYP7A1. (A) CES1A1 and BSEP guggulsterone response elements. The antioxidant response elements (ARE) are italicized,
whereas the activator protein-1 sites (AP-1) are bolded. (B) Multiple interplays among metabolism, CES1/BSEP induction, lipid retention, and bile acid synthesis The arrows point to the targets that
an enzyme or compound acts on or is converted into. When two
arrows points to the same target, the solid line denotes a major effect and the dotted line denotes a minor effect. The double-lined
arrow denotes an increased role when the induction of CES1 exceeds the capacity of bile acid synthesis.
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(Fig. 1B); and interestingly, the suppression was partially
reversed by Z-guggulsterone. These findings suggest
that Z-guggulsterone downregulates CYP7A1 through
both PXR and FXR, with FXR requiring higher presence
of bile acids. In addition, Z-guggulsterone and CDCA
synergistically induced BSEP (Fig. 1D), further weakening the feedback mechanism, although it remains to be
ascertained whether and to which extent the feed-back
mechanism contributes to the hypolipidemic activity of
Z-guggulsterone.
In summary, our study presents two interplays that likely
determine the overall hypolipidemic activity of guggul
(Fig. 7). The first interplay occurs between CES1 induction and CYP7A1 activity. CES1 induction within the capacity of CYP7A1 favors the synthesis of bile acids and
elimination of cholesterol. Excessive induction of CES1
beyond the capacity of CYP7A1 likely increases the engagement of this enzyme in the hydrolysis/reesterification cycle, favoring VLDL assembly. The second interplay occurs
between the metabolism of guggulsterones and the induction of BSEP/CES1. Increased metabolism enhances BSEP
induction and probably decreases the induction of CES1.
It is, therefore, expected that individuals with a higher
capacity of metabolizing guggulsterones (probably lower
dosing) will show lower induction of CES1 and have better
hypolipidemic outcomes.
The authors appreciate the use of the Core Facility supported
by National Center for Research Resources, National Institutes
of Health Grant P20 RR-016457.
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